ALK and non-small cell lung carcinoma: Currently, there are available some cdALK+ inhibitors (iALK+) for the treatment of ALK+ NSCLC patients: crizotinib as first generation; ceritinib, alectinib; brigatinib, lorlatinib and ensartinib from second and third generation, respectively [14–16].